Skip to content
buyWeak

Raymond Debbane bought $147k of LXRX

director at LEXICON PHARMACEUTICALS, INC.. 100,000 shares at an average of $1.47, traded Feb 23, 2026, filed Feb 25, 2026.

Conviction score
34
Value
$147k
100,000 shares
Holdings after
1,904,186
+6% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Director
    +15
  • Trade size
    $147k at market
    +11
  • Relative to holdings
    Holdings up 6%
    +3
  • Price context
    No price history yet
    0
  • Cluster
    No other insider buying within 14 days
    0
  • Repeat buying
    3 buys in 90 days
    +5
  • Track record
    Too few past buys to judge (0 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m +10.0%, 3m +44.7%, 6m +54.0%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

LXRXOct 9, 2026 · close 1.68
Since filing Feb 25, 2026: +12.0%SPY +13.1% · excess -1.1%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001062822-26-000032, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Feb 23, 2026POpen-market purchase
Common Stock
+100,000$1.47$147k1,904,186Feb 25, 2026

Related signals

Other insiders at LEXICON PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
15Weak
LXRXbuy
LEXICON PHARMACEUTICALS, INC.
Raymond Debbane
director
$2,980
2,000 shares
+0%
35Weak
LXRXbuy
LEXICON PHARMACEUTICALS, INC.
Raymond Debbane
director
$220k
150,000 shares
+9%
41Moderate
LXRXbuy 2
LEXICON PHARMACEUTICALS, INC.
Raymond Debbane
director
$353k
268,497 shares
+19%
56Moderate
LXRXbuy 2
LEXICON PHARMACEUTICALS, INC.
Invus Global Management, LLC
director, owner
$2.0M
1,538,462 shares
-
69Notable
LXRXbuy 2
LEXICON PHARMACEUTICALS, INC.
Lonnel Coats
Chief Executive Officer
$95k
90,000 shares
+11%
63Notable
LXRXbuy 2
LEXICON PHARMACEUTICALS, INC.
Philippe Amouyal
director
$202k
200,000 shares
+496%
51Moderate
LXRXbuy 2
LEXICON PHARMACEUTICALS, INC.
Lonnel Coats
Chief Executive Officer
$10k
10,000 shares
+1%
58Moderate
LXRXbuy
LEXICON PHARMACEUTICALS, INC.
Raymond Debbane
director
$1.1M
1,000,000 shares
+293%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Raymond Debbane bought $147k of LXRX | InsiderTell